Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTXFree Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.

CGTX has been the topic of a number of other research reports. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 19th. Finally, HC Wainwright raised their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $8.30.

Check Out Our Latest Research Report on CGTX

Cognition Therapeutics Stock Up 0.3 %

CGTX opened at $0.76 on Monday. The firm has a market cap of $31.61 million, a P/E ratio of -0.78 and a beta of 0.95. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The business’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.69.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently modified their holdings of CGTX. Mercer Global Advisors Inc. ADV grew its holdings in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. Sigma Planning Corp grew its holdings in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics during the 3rd quarter worth about $27,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Cognition Therapeutics during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

(Get Free Report)

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

Featured Articles

Analyst Recommendations for Cognition Therapeutics (NASDAQ:CGTX)

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.